Postmenopausal hormone treatment and the risk for malignancies

Menopausal hormone therapy (MHT), also known as hormone replacement therapy (HRT) is associated with specific risk constellations. The main risk familiar to patients is breast cancer, but there is also ongoing discussion about ovarian and endometrial cancer. The lecture focuses on the optimal treatment regimen to avoid increased risks for malignant diseases. Low dose estrogen therapy accompanied by natural progesterone or dydrogesterone seems to be the safest regimen from today’s perspective. Literature lacks reliable long-term data on the safety of testosterone replacement therapy